Clinical Trial Update: Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) [Phase 3]

View source ↗

Summary

Phase 3 open-label study evaluating oral ibrexafungerp (SCY-078) for invasive candidiasis and candidemia caused by Candida auris was completed. Results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• Brexafemme (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Candidiasis, Invasive, Candidemia | Phase 3 | Status: COMPLETED | Results posted: 2024-07-03